Literature DB >> 7957514

Effect of fluconazole on theophylline disposition in humans.

H Konishi1, K Morita, A Yamaji.   

Abstract

The effect of fluconazole, an antimycotic that inhibits cytochrome P-450-mediated drug metabolism, on theophylline kinetics and the production of its metabolites were compared with those of enoxacin in 5 healthy subjects. All subjects received a single oral dose of 240 mg theophylline (aminophylline, 300 mg) after they had been given oral fluconazole 100 mg every 12 h or enoxacin 200 mg every 8 h for three consecutive days. Pretreatment with enoxacin decreased the total clearance (CLT) and elimination rate constant (Kel) of theophylline by 50% and 46%, respectively, without changing the volume of distribution (Vd), but there were no significant change in any pharmacokinetic parameter when fluconazole was administered. Enoxacin led to a 50% reduction in the metabolic clearance (CLM) of theophylline and to decreases of 69%, 59% and 38% in the formation clearance of the three theophylline metabolites, 3-methylxanthine (3-MX), 1-methyluric acid (1-MU), and 1,3-dimethyluric acid (1,3-DMU), respectively, accompanied by significant changes in the urinary recovery of theophylline and its metabolites. In contrast, treatment with fluconazole led only to a slight decrease in the CLM of theophylline (16%) and in the formation clearance of its metabolites (15%-18%), and there was no change in the renal clearance (CLR) of theophylline. The results indicate that fluconazole is a minor inhibitor of theophylline disposition compared with enoxacin, and they suggest that the inhibitory action of fluconazole is selective for certain cytochrome P-450 isozymes, but not for the cytochrome P-4501A involved in theophylline metabolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957514     DOI: 10.1007/BF00194397

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

2.  Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study.

Authors:  D M Canafax; N M Graves; D M Hilligoss; B C Carleton; M J Gardner; A J Matas
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Azole antifungal drugs: old and new.

Authors:  W E Dismukes
Journal:  Ann Intern Med       Date:  1988-08-01       Impact factor: 25.391

4.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

5.  Effect of fluconazole on the disposition of phenytoin.

Authors:  R A Blum; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; N J Harrison; J J Schentag
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

6.  Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.

Authors:  M A Touchette; P H Chandrasekar; M A Milad; D J Edwards
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 7.  Fluconazole: a new antifungal agent.

Authors:  S F Kowalsky; D M Dixon
Journal:  Clin Pharm       Date:  1991-03

8.  [Pharmacokinetic evaluation of fluconazole in healthy volunteers].

Authors:  K Shiba; A Saito; T Miyahara
Journal:  Jpn J Antibiot       Date:  1989-01

9.  Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole.

Authors:  K Morita; H Konishi; H Shimakawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-05       Impact factor: 1.645

10.  Enoxacin--a potent inhibitor of theophylline metabolism.

Authors:  J Beckmann; W Elsässer; U Gundert-Remy; R Hertrampf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  7 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.

Authors:  M T Borin; S R Cox; B D Herman; B J Carel; R D Anderson; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 6.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

7.  Fluconazole (Diflucan).

Authors:  L M Hollier; S M Cox
Journal:  Infect Dis Obstet Gynecol       Date:  1995
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.